<DOC>
	<DOCNO>NCT01332461</DOCNO>
	<brief_summary>This retrospective cross-sectional database study use administrative data ( study period : 1/1/2003 7/31/2008 ) . Managed care enrollee ( age &gt; 40 year ) least one Hospitalization primary secondary diagnosis COPD ( ICD code 491.xx , 492.xx 496.xx ) least one Emergency Room ( ER ) visit primary diagnosis COPD ( index event ) study period target population . All subject require one year pre-index period baseline data . COPD event interest ER , Hospital physician visit follow oral corticosteroid ( OCS ) antibiotic ( Ab ) within 7 day . Other censor event treatment switch ; loss enrollment ; &gt; 60-day gap medication fill ; end study period . This study non descriptive hypothesis test study . Key study hypothesis list . Specifically study hypothesis primary outcome test : Ho : There difference risk COPD-related hospitalization FSC OMT Ha : There difference risk COPD-related hospitalization FSC OMT Hypothesis key secondary outcome COPD-related cost test : Ho : There difference COPD-related cost FSC OMT Ha : There difference COPD-related cost FSC OMT</brief_summary>
	<brief_title>Chronic Obstructive Pulmonary Disease ( COPD ) -Related Healthcare Utilization Costs After Discharge From Hospitalization Emergency Department Visit Regimen Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>At least one hospitalization primary secondary diagnosis COPD least one ER visit primary diagnosis COPD Initiatiation ( prescription ) FSC nonFSC ( i.e . TIO , ICS , LABA , IPR ) periindex period At least 40 year age Continuous eligibility preindex , periindex , followup period Exclusion Criteria Presence exclusionary comorbid condition preindex , periindex , followup period : respiratory cancer , cystic fibrosis , fibrosis due TB , bronchiectasis , pneumonociosis , pulmonary fibrosis , pulmonary tuberculosis , sarcoidosis Controller medication use periindex period COPDrelated hospitalization , ER visit , physician visit plus OCS/Abx within 3 day visit periindex period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>